The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
The current understanding of KRAS protein structure and dynamics
Open accessAbstract
One of the most common drivers in human cancer is the mutant KRAS protein. Not so long ago KRAS was considered as an undruggable oncoprotein. After a long struggle, however, we finally see some light at the end of the tunnel as promising KRAS targeted therapies are in or approaching clinical trials. In recent years, together with the promising progress in RAS drug discovery, our understanding of KRAS has increased tremendously. This progress has been accompanied with a resurgence of publicly available KRAS structures, which were limited to nine structures less than ten years ago. Furthermore, the ever-increasing computational capacity has made biologically relevant timescales accessible, enabling molecular dynamics (MD) simulations to study the dynamics of KRAS protein in more detail at the atomistic level. In this minireview, my aim is to provide the reader an overview of the publicly available KRAS structural data, insights to conformational dynamics revealed by experiments and what we have learned from MD simulations. Also, I will discuss limitations of the current data and provide suggestions for future research related to KRAS, which would fill out the existing gaps in our knowledge and provide guidance in deciphering this enigmatic oncoprotein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walker, J. E., Saraste, M., Runswick, M. J., & Gay, N. J. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01276.x · Cited by 5,312
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Dynamic personalities of proteins
Henzler-Wildman, K., & Kern, D. (2007) · Nature · doi:10.1038/nature06522 · Cited by 2,545
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
The P-loop — a common motif in ATP- and GTP-binding proteins
Saraste, M., Sibbald, P. R., & Wittinghofer, A. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90281-f · Cited by 2,056
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 3×
“To point out, KRAS interacts with its effector proteins on top of these switch regions [5]; therefore, it is perhaps not surprising that KRAS tends to form protein–protein contacts in this interface also in the crystal environment.”
BackgroundGEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
Yeh, I.-C., & Hummer, G. (2004) · The Journal of Physical Chemistry B · doi:10.1021/jp0477147 · Cited by 1,522
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Protein Data Bank: the single global archive for 3D macromolecular structure data
wwPDB consortium, Burley, S. K., Berman, H. M., Bhikadiya, C., Bi, C., Chen, L., Costanzo, L. D., Christie, C., Duarte, J. M., Dutta, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky949 · Cited by 1,163
Hancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,059
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Drugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927 · cited 1×
“as a challenging target, which is difficult to drug [23].”
BackgroundMarkov State Models: From an Art to a Science
Husic, B. E., & Pande, V. S. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b12191 · Cited by 886
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · cited 3×
“even mutations at the same position display tissue-specific abilities to drive tumorigenesis in vivo [4,29,30].”
BackgroundMarkov state models of biomolecular conformational dynamics
Chodera, J. D., & Noé, F. (2014) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2014.04.002 · Cited by 776
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
Regulating the regulator: post-translational modification of RAS
Ahearn, I. M., Haigis, K., Bar-Sagi, D., & Philips, M. R. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3255 · Cited by 557
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490
Cryo-EM in drug discovery: achievements, limitations and prospects
Renaud, J.-P., Chari, A., Ciferri, C., Liu, W.-T., Rémigy, H.-W., Stark, H., & Wiesmann, C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.77 · Cited by 461
Structure-Function Relationships of the G Domain, a Canonical Switch Motif
Wittinghofer, A., & Vetter, I. R. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062708-134043 · Cited by 460
Drugging an undruggable pocket on KRAS
Kessler, D., Gmachl, M., Mantoulidis, A., Martin, L. J., Zoephel, A., Mayer, M., Gollner, A., Covini, D., Fischer, S., Gerstberger, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904529116 · Cited by 449
Hillig, R. C., Sautier, B., Schroeder, J., Moosmayer, D., Hilpmann, A., Stegmann, C. M., Werbeck, N. D., Briem, H., Boemer, U., Weiske, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812963116 · Cited by 388
KRAS Alleles: The Devil Is in the Detail
Haigis, K. M. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.08.006 · Cited by 373
Dynamic properties of the Ras switch I region and its importance for binding to effectors
Spoerner, M., Herrmann, C., Vetter, I. R., Kalbitzer, H. R., & Wittinghofer, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081441398 · Cited by 325
Multivalent Small-Molecule Pan-RAS Inhibitors
Welsch, M. E., Kaplan, A., Chambers, J. M., Stokes, M. E., Bos, P. H., Zask, A., Zhang, Y., Sanchez-Martin, M., Badgley, M. A., Huang, C. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.006 · Cited by 274
Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404639111 · Cited by 242
Best Practices for Foundations in Molecular Simulations [Article v1.0]
Braun, E., Gilmer, J., Mayes, H. B., Mobley, D. L., Monroe, J. I., Prasad, S., & Zuckerman, D. M. (2018) · Living Journal of Computational Molecular Science · doi:10.33011/livecoms.1.1.5957 · Cited by 239
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Hobbs, G. A., Baker, N. M., Miermont, A. M., Thurman, R. D., Pierobon, M., Tran, T. H., Anderson, A. O., Waters, A. M., Diehl, J. N., Papke, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1006 · Cited by 231
Mazhab-Jafari, M. T., Marshall, C. B., Smith, M. J., Gasmi-Seabrook, G. M. C., Stathopulos, P. B., Inagaki, F., Kay, L. E., Neel, B. G., & Ikura, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419895112 · Cited by 220
The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B
Lu, S., Jang, H., Nussinov, R., & Zhang, J. (2016) · Scientific Reports · doi:10.1038/srep21949 · Cited by 219
GTP-Dependent K-Ras Dimerization
Muratcioglu, S., Chavan, T. S., Freed, B. C., Jang, H., Khavrutskii, L., Freed, R. N., Dyba, M. A., Stefanisko, K., Tarasov, S. G., Gursoy, A., et al. (2015) · Structure · doi:10.1016/j.str.2015.04.019 · Cited by 202
Tissue-Specific Oncogenic Activity of KRASA146T
Poulin, E. J., Bera, A. K., Lu, J., Lin, Y.-J., Strasser, S. D., Paulo, J. A., Huang, T. Q., Morales, C., Yan, W., Cook, J., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1220 · Cited by 197
Protein—protein crystal‐packing contacts
Carugo, O., & Argos, P. (1997) · Protein Science · doi:10.1002/pro.5560061021 · Cited by 192
Reaction path of protein farnesyltransferase at atomic resolution
Long, S. B., Casey, P. J., & Beese, L. S. (2002) · Nature · doi:10.1038/nature00986 · Cited by 185
Ubiquitination of K-Ras Enhances Activation and Facilitates Binding to Select Downstream Effectors
Sasaki, A. T., Carracedo, A., Locasale, J. W., Anastasiou, D., Takeuchi, K., Kahoud, E. R., Haviv, S., Asara, J. M., Pandolfi, P. P., & Cantley, L. C. (2011) · Science Signaling · doi:10.1126/scisignal.2001518 · Cited by 182
Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ
Dharmaiah, S., Bindu, L., Tran, T. H., Gillette, W. K., Frank, P. H., Ghirlando, R., Nissley, D. V., Esposito, D., McCormick, F., Stephen, A. G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615316113 · Cited by 173
Regional Polysterism in the GTP-Bound Form of the Human c-Ha-Ras Protein,
Ito, Y., Yamasaki, K., Iwahara, J., Terada, T., Kamiya, A., Shirouzu, M., Muto, Y., Kawai, G., Yokoyama, S., Laue, E. D., et al. (1997) · Biochemistry · doi:10.1021/bi970296u · Cited by 163
Structure of mammalian protein geranylgeranyltransferase type‐I
Taylor, J. S., Reid, T. S., Terry, K. L., Casey, P. J., & Beese, L. S. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg571 · Cited by 157
PDBe: improved accessibility of macromolecular structure data from PDB and EMDB
Velankar, S. S., van Ginkel, G., Alhroub, Y., Battle, G. M., Berrisford, J. M., Conroy, M. J., Dana, J. M., Gore, S. P., Gutmanas, A., Haslam, P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1047 · Cited by 154
The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M. R., Li, L.-S., Ren, P., Liu, Y., & Zarrinkar, P. P. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0061-5 · Cited by 153
Spoerner, M., Hozsa, C., Poetzl, J. A., Reiss, K., Ganser, P., Geyer, M., & Kalbitzer, H. R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.145235 · Cited by 148
LiteMol suite: interactive web-based visualization of large-scale macromolecular structure data
Sehnal, D., Deshpande, M., Vařeková, R. S., Mir, S., Berka, K., Midlik, A., Pravda, L., Velankar, S. S., & Koča, J. (2017) · Nature Methods · doi:10.1038/nmeth.4499 · Cited by 148
Cruz-Migoni, A., Canning, P., Quevedo, C. E., Bataille, C. J. R., Béry, N., Miller, A., Russell, A. J., Phillips, S. E. V., Carr, S. B., & Rabbitts, T. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811360116 · Cited by 144
Quevedo, C. E., Cruz-Migoni, A., Béry, N., Miller, A., Tanaka, T. U., Petch, D., Bataille, C. J. R., Lee, L. Y. W., Fallon, P. S., Tulmin, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05707-2 · Cited by 143
Prakash, P., Zhou, Y., Hong, L., Hancock, J. F., & Gorfe, A. A. (2016) · Biophysical Journal · doi:10.1016/j.bpj.2016.01.019 · Cited by 138
Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C
Zeng, M., Lu, J., Li, L., Feru, F., Quan, C., Gero, T. W., Ficarro, S. B., Xiong, Y., Ambrogio, C., Paranal, R. M., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.017 · Cited by 136
Johnson, C. W., Reid, D., Parker, J. A., Salter, S., Knihtila, R., Kuzmic, P., & Mattos, C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.778886 · Cited by 133 · cited 1×
“Since, it has been confirmed that the different isoforms exhibit distinct biochemical profiles [91].”
BackgroundKRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
Rabara, D., Tran, T. H., Dharmaiah, S., Stephens, R. M., McCormick, F., Simanshu, D. K., & Holderfield, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908353116 · Cited by 128
Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States
Gentile, D. R., Rathinaswamy, M. K., Jenkins, M. L., Moss, S. M., Siempelkamp, B. D., Renslo, A. R., Burke, J. E., & Shokat, K. M. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.025 · Cited by 128
Oncogenic Ras Isoforms Signaling Specificity at the Membrane
Nussinov, R., Tsai, C., & Jang, H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2727 · Cited by 126
Fell, J. B., Fischer, J. P., Baer, B. R., Ballard, J., Blake, J. F., Bouhana, K., Brandhuber, B. J., Briere, D. M., Burgess, L. E., Burkard, M. R., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00382 · Cited by 120
Regulation of RAS oncogenicity by acetylation
Yang, M. H., Nickerson, S., Kim, E. T., Liot, C., Laurent, G., Spang, R., Philips, M. R., Shan, Y., Shaw, D. E., Bar‐Sagi, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201487109 · Cited by 120
Long, S. B., Casey, P. J., & Beese, L. S. (2000) · Structure · doi:10.1016/s0969-2126(00)00096-4 · Cited by 114
Shin, Y., Jeong, J. W., Wurz, R. P., Achanta, P., Arvedson, T., Bartberger, M. D., Campuzano, I. D. G., Fucini, R., Hansen, S. K., Ingersoll, J., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00258 · Cited by 113
The mechanism of PI3Kα activation at the atomic level
Zhang, M., Jang, H., & Nussinov, R. (2019) · Chemical Science · doi:10.1039/c8sc04498h · Cited by 111
Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
Kano, Y., Gebregiworgis, T., Marshall, C. B., Radulovich, N., Poon, B. P. K., St-Germain, J., Cook, J. D., Valencia-Sama, I., Grant, B. M. M., Herrera, S. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08115-8 · Cited by 103 · cited 1×
“The tyrosine residues Y32 and Y64, in switch-I and switch-II, respectively, can be phosphorylated via c-Src [80].”
BackgroundWinters, I. P., Chiou, S., Paulk, N. K., McFarland, C. D., Lalgudi, P. V., Ma, R. K., Lisowski, L., Connolly, A. J., Petrov, D. A., Kay, M. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01519-y · Cited by 102
Kaiser, J., Simon, N. A., Sauseng, P., & Schütz‐Bosbach, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-49476-4 · Cited by 101
Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
Guillard, S., Kolasinska-Zwierz, P., Debreczeni, J. E., Breed, J., Zhang, J., Béry, N., Marwood, R., Tart, J., Overman, R., Stocki, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms16111 · Cited by 100
KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe
Bery, N., Legg, S., Debreczeni, J., Breed, J., Embrey, K., Stubbs, C., Kolasinska-Zwierz, P., Barrett, N., Marwood, R., Watson, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10419-2 · Cited by 97
Expanding the scope of electrophiles capable of targeting K-Ras oncogenes
McGregor, L. M., Jenkins, M. L., Kerwin, C., Burke, J. E., & Shokat, K. M. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00271 · Cited by 97
Oncogenic G12D mutation alters local conformations and dynamics of K-Ras
Vatansever, S., Erman, B., & Gumus, Z. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-48029-z · Cited by 96
Direct inhibition of RAS: Quest for the Holy Grail?
Spencer-Smith, R., & O’Bryan, J. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.005 · Cited by 95
Johnson, C. W., Lin, Y.-J., Reid, D., Parker, J., Pavlopoulos, S., Dischinger, P., Graveel, C., Aguirre, A. J., Steensma, M., Haigis, K. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.026 · Cited by 89
Lu, S., Banerjee, A., Jang, H., Zhang, J., Gaponenko, V., & Nussinov, R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664755 · Cited by 88
Integrated RAS signaling defined by parallel NMR detection of effectors and regulators
Smith, M. J., & Ikura, M. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1435 · Cited by 87 · cited 1×
“teins, diminished or enhanced binding, a clear on/off binding changes are not observed [4,110].”
BackgroundFang, Z., Marshall, C. B., Nishikawa, T., Gossert, A. D., Jansen, J. M., Jahnke, W., & Ikura, M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.07.009 · Cited by 86
Pantsar, T., Rissanen, S., Dauch, D., Laitinen, T., Vattulainen, I., & Poso, A. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006458 · Cited by 85
Self-citationMo, S. P., Coulson, J. M., & Prior, I. A. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180173 · Cited by 85
Sogabe, S., Kamada, Y., Miwa, M., Niida, A., Sameshima, T., Kamaura, M., Yonemori, K., Sasaki, S., Sakamoto, J.-I., & Sakamoto, K. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00128 · Cited by 83
Li, Z., & Buck, M. (2017) · Structure · doi:10.1016/j.str.2017.02.007 · Cited by 82
Sarkar‐Banerjee, S., Sayyed–Ahmad, A., Prakash, P., Cho, K., Waxham, M. N., Hancock, J. F., & Gorfe, A. A. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b06292 · Cited by 81
Parker, J. A., Volmar, A. Y., Pavlopoulos, S., & Mattos, C. (2018) · Structure · doi:10.1016/j.str.2018.03.018 · Cited by 81
Structures of N-terminally processed KRAS provide insight into the role of N-acetylation
Dharmaiah, S., Tran, T. H., Messing, S. A. J., Agamasu, C., Gillette, W., Yan, W., Waybright, T. J., Alexander, P., Esposito, D., Nissley, D. V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46846-w · Cited by 81
High-affinity interaction of the K-Ras4B hypervariable region with the RAS active site
Chavan, T. S., Jang, H., Khavrutskii, L., Abraham, S. J., Banerjee, A., Freed, B. C., Johannessen, L., Tarasov, S. G., Gaponenko, V., Nussinov, R., et al. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2015.09.034 · Cited by 79
The higher level of complexity of K‐Ras4B activation at the membrane
Jang, H., Banerjee, A., Chavan, T., Lu, S., Zhang, J., Gaponenko, V., & Nussinov, R. (2015) · The FASEB Journal · doi:10.1096/fj.15-279091 · Cited by 77
Alvarez-Moya, B., López-Alcalá, C., Drosten, M., Bachs, O., & Agell, N. (2010) · Oncogene · doi:10.1038/onc.2010.298 · Cited by 75
The structural basis for Ras activation of PI3Kα lipid kinase
Zhang, M., Jang, H., & Nussinov, R. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp00101h · Cited by 74
K-Ras4B Remains Monomeric on Membranes over a Wide Range of Surface Densities and Lipid Compositions
Chung, J. K., Lee, Y. K., Denson, J.-P., Gillette, W., Alvarez, S. A., Stephen, A. G., & Groves, J. T. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2017.10.042 · Cited by 68
Covalent Guanosine Mimetic Inhibitors of G12C KRAS
Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H. G., Lim, S. M., Manandhar, A., Gondi, S., Sim, T., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00373 · Cited by 66
An engineered protein antagonist of K-Ras/B-Raf interaction
Kauke, M. J., Traxlmayr, M. W., Parker, J. A., Kiefer, J. D., Knihtila, R., McGee, J., Verdine, G., Mattos, C., & Wittrup, K. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-05889-7 · Cited by 64
Structural insight into the rearrangement of the switch I region in GTP-bound G12A K-Ras
Xu, S., Long, B. N., Boris, G. H., Chen, A., Ni, S., & Kennedy, M. A. (2017) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798317015418 · Cited by 63
Phosphorylation at Ser-181 of Oncogenic KRAS Is Required for Tumor Growth
Barceló, C., Paco, N., Morell, M., Alvarez-Moya, B., Bota‐Rabassedas, N., Jaumot, M., Vilardell, F., Capellá, G., & Agell, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1750 · Cited by 62
Dynamics of Membrane-Bound G12V-KRAS from Simulations and Single-Molecule FRET in Native Nanodiscs
Prakash, P., Litwin, D. B., Hong, L., Sarkar‐Banerjee, S., Dolino, D. M., Zhou, Y., Hancock, J. F., Jayaraman, V., & Gorfe, A. A. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.12.011 · Cited by 62
Béry, N., Cruz-Migoni, A., Bataille, C. J. R., Quevedo, C. E., Tulmin, H., Miller, A., Russell, A. J., Phillips, S. E. V., Carr, S. B., & Rabbitts, T. H. (2018) · eLife · doi:10.7554/elife.37122 · Cited by 61
Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange
Nnadi, C. I., Jenkins, M. L., Gentile, D. R., Bateman, L. A., Zaidman, D., Balius, T. E., Nomura, D. K., Burke, J. E., Shokat, K. M., & London, N. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00399 · Cited by 60
Chakrabarti, M., Jang, H., & Nussinov, R. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b11110 · Cited by 59
Intrinsic protein disorder in oncogenic KRAS signaling
Nussinov, R., Jang, H., Tsai, C., Liao, T.-J., Li, S., Fushman, D., & Zhang, J. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2564-3 · Cited by 59
Welman, A., Burger, M. M., & Hagmann, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203818 · Cited by 56
Sayyed-Ahmad, A., Prakash, P., & Gorfe, A. A. (2017) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25317 · Cited by 54
Differential dynamics of RAS isoforms in GDP- and GTP-bound states
Kapoor, A., & Travesset, A. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24805 · Cited by 53
KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation
Lu, J., Bera, A. K., Gondi, S. R., & Westover, K. D. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00974 · Cited by 53
Lessons from computer simulations of Ras proteins in solution and in membrane
Prakash, P., & Gorfe, A. A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.07.024 · Cited by 51
Probing the Conformational and Energy Landscapes of KRAS Membrane Orientation
Prakash, P., & Gorfe, A. A. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.9b05796 · Cited by 51
Bermudez, M., Mortier, J., Rakers, C., Sydow, D., & Wolber, G. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.001 · Cited by 49
AMG 510 First to Inhibit “Undruggable” KRAS
(2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2019-073 · Cited by 47
Sun, Q., Phan, J., Friberg, A., Camper, D. V., Olejniczak, E. T., & Fesik, S. W. (2014) · Journal of Biomolecular NMR · doi:10.1007/s10858-014-9849-8 · Cited by 42
Exceptionally high-affinity Ras binders that remodel its effector domain
McGee, J. H., Shim, S. Y., Lee, S., Swanson, P. K., Jiang, S. Y., Durney, M. A., & Verdine, G. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816348 · Cited by 42
Nussinov, R., Tsai, C., & Jang, H. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.002 · Cited by 42
Insights into K-Ras 4B regulation by post-translational lysine acetylation
Knyphausen, P., Lang, F., Baldus, L., Extra, A., & Lammers, M. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0118 · Cited by 39
Lu, J., Harrison, R. A., Li, L., Zeng, M., Gondi, S. R., Scott, D. A., Gray, N. S., Engen, J. R., & Westover, K. D. (2017) · Structure · doi:10.1016/j.str.2017.07.003 · Cited by 39
The Structural Basis of the Farnesylated and Methylated KRas4B Interaction with Calmodulin
Jang, H., Banerjee, A., Marcus, K., Makowski, L., Mattos, C., Gaponenko, V., & Nussinov, R. (2019) · Structure · doi:10.1016/j.str.2019.08.009 · Cited by 35
Structural basis of the atypical activation mechanism of KRASV14I
Bera, A. K., Lu, J., Wales, T. E., Gondi, S. R., Gurbani, D., Nelson, A., Engen, J. R., & Westover, K. D. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009131 · Cited by 32
Oncogenic KRas mobility in the membrane and signaling response
Nussinov, R., Tsai, C., & Jang, H. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.009 · Cited by 25
Bergner, A., Cockcroft, X. F., Fischer, G. W., Gollner, A., Hela, W., Kousek, R., Mantoulidis, A., Martin, L. J., Mayer, M., Müllauer, B., et al. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201902810 · Cited by 23
Expression, purification, and characterization of soluble K-Ras4B for structural analysis
Abraham, S. J., Muhamed, I., Nolet, R., Yeung, F., & Gaponenko, V. (2010) · Protein Expression and Purification · doi:10.1016/j.pep.2010.05.015 · Cited by 21
Organization of Farnesylated, Carboxymethylated KRAS4B on Membranes
Barklis, E., Stephen, A. G., Staubus, A. O., Barklis, R. L., & Alfadhli, A. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.07.025 · Cited by 19
Johnson, C. W., Lin, Y.-J., Reid, D. F., Parker, J. A., Dischinger, P. S., Graveel, C. R., Pavlopoulos, S., Steensma, M. R., Haigis, K. M., & Mattos, C. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3312728 · Cited by 2
Research works printed but not linked: 3
- Rapp C.S. and Pollack R.M.: Crystal packing effects on protein loops. Proteins 2005; 60: 103. · DOI
- Grossfield A., Patrone P.N., Roe D.R., Schultz A.J., Siderius D.W. and Zuckerman D.M.: Best practices for quantification of uncertainty and sampling quality in molecular simulations [Article v1.0]. Living J Comput Mol Sci 2018; 1.
- Vögele M., Köfinger J. and Hummer G.: Finite-size-corrected rotational diffusion coefficients of membrane proteins and carbon nanotubes from molecular dynamics simulations. J Phys Chem B 2019; 123: 5099. · doi:10.1021/acs.jpcb.9b01656
Cited by
Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Salo-Ahen, O. M. H., Alanko, I., Bhadane, R., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A. S., et al. (2020) · Processes · doi:10.3390/pr9010071 · Cited by 659
Self-citationThe current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
A deep catalogue of protein-coding variation in 983,578 individuals
Sun, K. Y., Bai, X., Chen, S., Bao, S., Zhang, C., Kapoor, M., Backman, J., Joseph, T., Maxwell, E., Mitra, G., et al. (2024) · Nature · doi:10.1038/s41586-024-07556-0 · Cited by 127
Issahaku, A. R., Mukelabai, N., Agoni, C., Rudrapal, M., Aldosari, S. M., Almalki, S. G., & Khan, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-22668-1 · Cited by 93
Johnson, C. W., Lin, Y.-J., Reid, D., Parker, J., Pavlopoulos, S., Dischinger, P., Graveel, C., Aguirre, A. J., Steensma, M., Haigis, K. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.026 · Cited by 89
Metadata
- Authors
- Pantsar, T.
- Venue
- Computational and Structural Biotechnology Journal
- Published
- 2020
- Volume
- 18
- Pages
- 189-198
- ISSN
- 2001-0370 (ISSN-L)
- OpenAlex
- W2998581726
- Cited by
- 282
- References
- 114
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Horizon 2020
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.